Effectiveness，Safety，Thymic Cancer
1 clinical trials · Condition
◉ Watch Effectiveness，Safety，Thymic Cancer
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer (NCT04975061) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2021-08-01 |
Track Effectiveness，Safety，Thymic Cancer automatically
Every clearance here is in the API, with alerts when new ones post.